Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Active not recruiting 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 22OTHER 19NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Recurrence 1Multiple Myeloma 1

Interventions

Radiotherapy 41Cisplatin 36Fluorouracil 17Paclitaxel 15Docetaxel 14Cyclophosphamide 14Carboplatin 14Filgrastim 13Doxorubicin 13Gemcitabine 11Etoposide 11Capecitabine 10Surgical Procedures, Operative 9Methotrexate 9Leucovorin 9Chemotherapy, Adjuvant 9Vincristine 8Peripheral Blood Stem Cell Transplantation 8Oxaliplatin 8Dexamethasone 7Bevacizumab 7Topotecan 6Radiotherapy, Conformal 6Prednisone 6Fenretinide 6Cetuximab 6Neoadjuvant Therapy 5Mitomycin 5Irinotecan 5Ifosfamide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × NETWORK × pomalidomide × Clear all
NCT04150965 2025-02-14

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Multiple Myeloma Research Consortium

Phase 1/2 Terminated
14 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡